Octagon Capital Advisors LP
CIK 1839435 · View on SEC EDGAR ↗
- Portfolio value
- $1.1B
- Positions
- 27
- As of
- June 30, 2026
#2,279 of 9,443 by 13F value · top 24.1%
Portfolio value QoQ: +23.1% 13F does not disclose cash
- Top 10 holdings weight
- 78.54%
- Top 25 holdings weight
- 99.73%
- Positions above 1%
- 18
- Effective number of positions
- 12.1
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 14.79% Est. buys $149,131,455 · sells $170,419,111
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 39.1% still held
- New positions
- 5
- Increased
- 4
- Decreased
- 6
- Closed
- 7
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +102.5% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 94.3% · Options excluded: 1.8%
Sector breakdown
Healthcare
82.7%
Other/Unmapped
17.3%
Full portfolio 27 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $179,525,699 | 16.14% | 1,841,667 | $16,161,404 | Down ×2 | ||
| DFTX Definium Therapeutics, Inc. - Common Shares | $138,768,000 | 12.47% | 2,950,000 | $92,652,000 | Up ×1 | ||
| ABVX Abivax SA - American Depositary Shares | $132,327,180 | 11.89% | 993,000 | $56,943,230 | Up ×1 | ||
| COGT Cogent Biosciences, Inc. - Common Stock | $90,945,000 | 8.17% | 2,350,000 | $493,500 | |||
| ALMS Alumis Inc. - Common Stock | $79,655,898 | 7.16% | 2,830,700 | $17,295,577 | |||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $68,474,416 | 6.15% | 1,971,054 | $23,002,200 | |||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $66,010,992 | 5.93% | 9,693,244 | $26,407,190 | Up ×1 | ||
| BIOA BioAge Labs, Inc. - Common Stock | $42,843,480 | 3.85% | 1,748,000 | $12,270,960 | |||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $39,675,023 | 3.57% | 338,900 | $8,367,441 | |||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $35,547,700 | 3.20% | 310,000 | $149,450 | Down ×2 | ||
| AKTS Aktis Oncology, Inc. - Common stock | $30,968,099 | 2.78% | 960,847 | $13,778,546 | |||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $29,576,400 | 2.66% | 490,000 | $1,082,900 | |||
| Unknown issuer (CUSIP: 29479A908) | $22,991,600 | 2.07% | 1,255,000 | Call option | Up ×1 | ||
| PALI Palisade Bio, Inc. - Common Stock | $21,477,503 | 1.93% | 10,276,317 | $3,493,948 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $20,376,500 | 1.83% | 2,075,000 | $-6,444,602 | Down ×1 | ||
| IRON Disc Medicine, Inc. - Common Stock | $19,747,800 | 1.78% | 270,000 | $2,484,000 | |||
| SMMT Summit Therapeutics Inc. - Common Stock | $18,212,500 | 1.64% | 1,250,000 | Up ×1 | |||
| PHVS Pharvaris N.V. - Ordinary Shares | $15,793,412 | 1.42% | 456,721 | $11,132,162 | Up ×1 | ||
| ANL Adlai Nortye Ltd. - American Depositary Shares | $10,749,234 | 0.97% | 934,716 | Up ×1 | |||
| DTIL Precision BioSciences, Inc. - Common Stock | $10,611,000 | 0.95% | 1,350,000 | $-1,691,026 | Down ×1 | ||
| DBVT DBV Technologies S.A. - American Depositary Shares | $9,416,880 | 0.85% | 574,200 | $-2,578,158 | |||
| SNSE Sensei Biotherapeutics, Inc. - Common Stock | $9,025,250 | 0.81% | 361,010 | Up ×1 | |||
| GYRE Gyre Therapeutics, Inc. - Common Stock | $6,289,601 | 0.57% | 954,416 | Up ×1 | |||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $5,874,750 | 0.53% | 315,000 | $-11,841,300 | Down ×2 | ||
| UNCY Unicycive Therapeutics, Inc. - Common Stock | $4,690,000 | 0.42% | 1,000,000 | $-1,890,000 | |||
| CNTX Context Therapeutics Inc. - Common Stock | $1,689,395 | 0.15% | 3,050,000 | $-12,065,605 | Down ×1 | ||
| GOSS Gossamer Bio, Inc. - Common Stock | $1,275,650 | 0.11% | 7,750,000 | $-1,270,225 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| DFTX | Bought more | +510K | +$92.7M |
| ABVX | Bought more | +316K | +$56.9M |
| TSHA | Bought more | +833K | +$26.4M |
| AVBP | Price move only | +0 | +$23.0M |
| ALMS | Price move only | +0 | +$17.3M |
| DNTH | Trimmed | -105K | +$16.2M |
| AKTS | Price move only | +0 | +$13.8M |
| BIOA | Price move only | +0 | +$12.3M |
| TRVI | Trimmed | -1.2M | -$11.8M |
| PHVS | Bought more | +292K | +$11.1M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| INSM | March 31, 2025 | 582,000 | $40,181,280 | 64.4% |
| VRNA | Sept. 30, 2025 | 337,000 | $31,873,460 | No longer tracked |
| MNMD | March 31, 2026 | 2,230,000 | $29,859,700 | No longer tracked |
| CNTA | June 30, 2026 | 750,000 | $29,790,000 | No longer tracked |
| KALV | June 30, 2026 | 1,450,000 | $29,188,500 | No longer tracked |
| MRUS | Dec. 31, 2025 | 308,000 | $28,998,200 | No longer tracked |
| TERN | June 30, 2026 | 530,000 | $27,941,600 | No longer tracked |
| CGON | March 31, 2026 | 600,000 | $24,912,000 | 15.6% |
| SPRY | Sept. 30, 2025 | 1,350,000 | $23,557,500 | -44.5% |
| CDTX | March 31, 2026 | 100,000 | $22,089,000 | No longer tracked |
| APLS | Dec. 31, 2025 | 903,500 | $20,446,205 | No longer tracked |
| RAPT | March 31, 2026 | 574,000 | $19,441,380 | No longer tracked |
| ATYR | Sept. 30, 2025 | 3,820,000 | $19,367,400 | -27.9% |
| DYN | March 31, 2025 | 668,000 | $15,738,080 | 152.3% |
| TRML | Sept. 30, 2025 | 905,000 | $14,470,950 | No longer tracked |
| BBIO | March 31, 2025 | 441,600 | $12,117,504 | 139.1% |
| SNDX | June 30, 2025 | 904,000 | $11,105,640 | 111.5% |
| SRRK | June 30, 2025 | 329,000 | $10,577,350 | 55.6% |
| VSTM | June 30, 2025 | 1,720,000 | $10,371,600 | 67.5% |
| NUVB | Dec. 31, 2025 | 2,633,334 | $9,743,336 | -22.0% |
| RGLS | June 30, 2025 | 4,637,076 | $8,114,883 | No longer tracked |
| CRBP | March 31, 2026 | 955,000 | $7,773,700 | 6.7% |
| MLTX | Sept. 30, 2025 | 148,000 | $6,985,600 | 121.2% |
| BBOT | June 30, 2026 | 719,000 | $6,435,050 | 22.0% |
| LXEO | June 30, 2026 | 1,100,000 | $6,314,000 | 10.5% |
| VRDN | June 30, 2025 | 450,000 | $6,066,000 | 76.1% |
| CATX | June 30, 2025 | 2,250,000 | $4,792,500 | No longer tracked |
| ALVR | March 31, 2025 | 11,215,000 | $4,710,300 | No longer tracked |
| MAZE | Dec. 31, 2025 | 177,667 | $4,606,905 | -29.8% |
| PEPG | March 31, 2026 | 700,000 | $4,557,000 | 77.4% |
| NGNE | Dec. 31, 2025 | 252,000 | $4,367,160 | 86.6% |
| CATX | June 30, 2026 | 791,555 | $3,300,784 | No longer tracked |
| EVMN | June 30, 2026 | 143,472 | $3,298,421 | 5.6% |
| GPCR | Dec. 31, 2025 | 115,000 | $3,220,000 | -26.9% |
| HLXB | Sept. 30, 2025 | 250,000 | $2,662,500 | No longer tracked |
| MRSN | March 31, 2025 | 992,000 | $1,418,560 | No longer tracked |
| KLRS | Sept. 30, 2025 | 360,000 | $961,200 | -29.1% |
| ERAS | Sept. 30, 2025 | 700,000 | $889,000 | 708.7% |
| NUVBWS | Dec. 31, 2025 | 104,112 | $385,214 | No longer tracked |